Pertuza (pertuzumab biosimilar) / Alkem Labs, Hetero - LARVOL DELTA

Theranostics as a Personalized Clinical Approach in CNS Tumors (SNMMI 2026) - "A therapeutic emitting radionuclide such as 177Lu-DOTA-TATE can then be initiated as targeted therapy...In patients with cerebral metastases from prostate cancer, PSMA-targeted therapy using 177Lu-PSMA-617 and 177Ac-PSMA-617 effectively reduced brain tumor size, with changes in PSMA expression accurately tracked using PSMA-PET/CT...Feasibility studies with 89Zr-trastuzumab, 64Cu-DOTA-trastuzumab, and 89Zr-pertuzamab have successfully identified HER2-positive breast cancer metastases to the brain...Initial clinical trials studying 11C-erlotinib,11C-lapatinib, and 11C-osimertinib demonstrated selective uptake by tumor tissue in breast and lung cancer metastases to the brain... Theranostics is an emerging field of precision medicine that enables accurate, localized delivery of therapy to cancerous tissue. PET-guided treatment of CNS tumors presents a unique opportunity for patient management, especially for those refractory to existing treatment options. This treatment..."

Clinical • First-in-human • Brain Cancer • Breast Cancer • Castration-Resistant Prostate Cancer • CNS Tumor • Genito-urinary Cancer • Genitourinary Neuroendocrine Tumor • Glioblastoma • Glioma • HER2 Breast Cancer • HER2 Positive Breast Cancer • Low Grade Glioma • Lung Cancer • Meningioma • Neuroendocrine Tumor • Oncology • Prostate Cancer • Solid Tumor • FOLH1 • HER-2 • SSTR • SSTR2

Theranostics as a Personalized Clinical Approach in CNS Tumors (SNMMI 2026) - "A therapeutic emitting radionuclide such as 177Lu-DOTA-TATE can then be initiated as targeted therapy...In patients with cerebral metastases from prostate cancer, PSMA-targeted therapy using 177Lu-PSMA-617 and 177Ac-PSMA-617 effectively reduced brain tumor size, with changes in PSMA expression accurately tracked using PSMA-PET/CT...Feasibility studies with 89Zr-trastuzumab, 64Cu-DOTA-trastuzumab, and 89Zr-pertuzamab have successfully identified HER2-positive breast cancer metastases to the brain...Initial clinical trials studying 11C-erlotinib,11C-lapatinib, and 11C-osimertinib demonstrated selective uptake by tumor tissue in breast and lung cancer metastases to the brain... Theranostics is an emerging field of precision medicine that enables accurate, localized delivery of therapy to cancerous tissue. PET-guided treatment of CNS tumors presents a unique opportunity for patient management, especially for those refractory to existing treatment options. This treatment..."

Clinical • First-in-human • Brain Cancer • Breast Cancer • Castration-Resistant Prostate Cancer • CNS Tumor • Genito-urinary Cancer • Genitourinary Neuroendocrine Tumor • Glioblastoma • Glioma • HER2 Breast Cancer • HER2 Positive Breast Cancer • Low Grade Glioma • Lung Cancer • Meningioma • Neuroendocrine Tumor • Oncology • Prostate Cancer • Solid Tumor • FOLH1 • HER-2 • SSTR • SSTR2

Alkem launches Roche's breast cancer blockbuster biosimilar alternative in India (The Economic Times)

Biosimilar launch • HER2 Positive Breast Cancer